Janus Henderson Group PLC Grows Stake in Applied Therapeutics, Inc. (NASDAQ:APLT)

Janus Henderson Group PLC grew its position in shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 37.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,541,528 shares of the company's stock after purchasing an additional 2,893,323 shares during the period. Janus Henderson Group PLC owned approximately 9.06% of Applied Therapeutics worth $89,656,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. lifted its holdings in shares of Applied Therapeutics by 17.1% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company's stock valued at $10,676,000 after acquiring an additional 333,278 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Applied Therapeutics by 165.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 735,217 shares of the company's stock valued at $6,249,000 after acquiring an additional 457,940 shares during the last quarter. Peregrine Capital Management LLC bought a new position in shares of Applied Therapeutics in the 2nd quarter valued at about $3,414,000. Ally Bridge Group NY LLC bought a new stake in Applied Therapeutics in the third quarter worth about $5,256,000. Finally, Bank of New York Mellon Corp bought a new stake in Applied Therapeutics in the second quarter worth about $1,325,000. Hedge funds and other institutional investors own 98.31% of the company's stock.

Applied Therapeutics Stock Down 6.5 %

APLT stock traded down $0.09 during trading on Thursday, hitting $1.29. 10,305,015 shares of the company's stock traded hands, compared to its average volume of 2,369,568. The firm has a market capitalization of $150.10 million, a P/E ratio of -0.80 and a beta of 1.76. The business has a fifty day simple moving average of $8.18 and a two-hundred day simple moving average of $6.36. Applied Therapeutics, Inc. has a 1 year low of $1.20 and a 1 year high of $10.62.

Analyst Upgrades and Downgrades

Several analysts have issued reports on APLT shares. Leerink Partners raised their price objective on shares of Applied Therapeutics from $11.00 to $14.00 and gave the stock an "outperform" rating in a research note on Thursday, September 19th. UBS Group reissued a "neutral" rating and issued a $2.00 price objective (down previously from $13.00) on shares of Applied Therapeutics in a research note on Monday. Royal Bank of Canada lowered shares of Applied Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their target price for the stock from $12.00 to $4.00 in a research report on Friday, November 29th. William Blair raised shares of Applied Therapeutics to a "strong-buy" rating in a research report on Thursday, November 28th. Finally, Robert W. Baird reduced their target price on shares of Applied Therapeutics from $14.00 to $5.00 and set an "outperform" rating on the stock in a research report on Friday, November 29th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $6.60.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.